About Peplin
Peplin is a company based in Emeryville (United States) founded in 1999 was acquired by LEO Pharma in September 2009. Peplin has completed 1 acquisition, including Neosil. Peplin operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Emeryville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$24 M (USD), Post-IPO
Aug 19, 2008
-
Investors
LEO Pharma
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
LEO Pharma
(Sep 03, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Peplin
Investors in Peplin
Peplin has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include LEO Pharma, Turmeric Acquisition Corp and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked | |
|
Developer of drugs for treating dermatology diseases
|
Locked | Locked | Locked |
Investor details for Peplin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Peplin
Peplin has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neosil.
Investment portfolio details for Peplin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Specialty dermatology pharmaceuticals were developed by US-based Neosil until acquisition.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Peplin
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Peplin
Detailed financials for Peplin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Peplin Comparisons
Peer comparison for Peplin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Peplin
Peplin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Peplin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Peplin
Complete news archive for Peplin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Peplin
Peplin was founded in 1999 and raised its 1st funding round 6 years after it was founded.
Peplin is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Tom Wiggans is the current CEO of Peplin.
Peplin was founded in 1999 in Emeryville, United States, with operations centered on medical dermatology. The company develops and commercializes products such as ingenol mebutate gel, known as PEP005, sourced from Euphorbia peplus for actinic keratosis treatment. Patents for this compounds use in dermatology are held by Peplin. As of November 2009, it functions as a wholly owned subsidiary of Leo Pharma.
Peplin's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Peplin has made 1 acquisition, including Neosil.
Peplin has 3 investors. Key investors include LEO Pharma, Turmeric Acquisition Corp, and NEA.